HC Wainwright & Co. Maintains Buy on SpringWorks Therapeutics, Raises Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reaffirmed a Buy rating on SpringWorks Therapeutics (NASDAQ:SWTX) and increased the price target from $64 to $73.
November 29, 2023 | 11:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SpringWorks Therapeutics' Buy rating is maintained by HC Wainwright & Co., with a raised price target from $64 to $73, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100